In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer
Roche’s Genentech was supposed to get a priority review for its combo using Tecentriq and Avastin plus chemo in frontline lung cancer cases, with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
